These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
160 related articles for article (PubMed ID: 21570154)
1. Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families. van der Rhee JI; de Snoo FA; Vasen HFA; Mooi WJ; Putter H; Gruis NA; Kukutsch NA; Bergman W J Am Acad Dermatol; 2011 Aug; 65(2):289-296. PubMed ID: 21570154 [TBL] [Abstract][Full Text] [Related]
2. Clinical and histologic characteristics of malignant melanoma in families with a germline mutation in CDKN2A. van der Rhee JI; Krijnen P; Gruis NA; de Snoo FA; Vasen HFA; Putter H; Kukutsch NA; Bergman W J Am Acad Dermatol; 2011 Aug; 65(2):281-288. PubMed ID: 21570156 [TBL] [Abstract][Full Text] [Related]
3. The Impact of Longitudinal Surveillance on Tumor Thickness for Melanoma-Prone Families with and without Pathogenic Germline Variants of Sargen MR; Pfeiffer RM; Elder DE; Yang XR; Goldstein AM; Tucker MA Cancer Epidemiol Biomarkers Prev; 2021 Apr; 30(4):676-681. PubMed ID: 33811164 [TBL] [Abstract][Full Text] [Related]
5. CDKN2A mutations in multiple primary melanomas. Monzon J; Liu L; Brill H; Goldstein AM; Tucker MA; From L; McLaughlin J; Hogg D; Lassam NJ N Engl J Med; 1998 Mar; 338(13):879-87. PubMed ID: 9516223 [TBL] [Abstract][Full Text] [Related]
6. Pediatric melanoma in melanoma-prone families. Goldstein AM; Stidd KC; Yang XR; Fraser MC; Tucker MA Cancer; 2018 Sep; 124(18):3715-3723. PubMed ID: 30207590 [TBL] [Abstract][Full Text] [Related]
7. Cancer risks and survival in patients with multiple primary melanomas: Association with family history of melanoma and germline CDKN2A mutation status. Helgadottir H; Tuominen R; Olsson H; Hansson J; Höiom V J Am Acad Dermatol; 2017 Nov; 77(5):893-901. PubMed ID: 28818438 [TBL] [Abstract][Full Text] [Related]
8. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation. van der Rhee JI; Boonk SE; Putter H; Cannegieter SC; Flinterman LE; Hes FJ; de Snoo FA; Mooi WJ; Gruis NA; Vasen HF; Kukutsch NA; Bergman W Cancer Epidemiol Biomarkers Prev; 2013 Oct; 22(10):1771-7. PubMed ID: 23897584 [TBL] [Abstract][Full Text] [Related]
10. Frequency of UV-inducible NRAS mutations in melanomas of patients with germline CDKN2A mutations. Eskandarpour M; Hashemi J; Kanter L; Ringborg U; Platz A; Hansson J J Natl Cancer Inst; 2003 Jun; 95(11):790-8. PubMed ID: 12783933 [TBL] [Abstract][Full Text] [Related]
11. Pediatric melanomas often mimic benign skin lesions: A retrospective study. Mitkov M; Chrest M; Diehl NN; Heckman MG; Tollefson M; Jambusaria-Pahlajani A J Am Acad Dermatol; 2016 Oct; 75(4):706-711.e4. PubMed ID: 27430613 [TBL] [Abstract][Full Text] [Related]
12. Biology of desmoplastic melanoma: a case-control comparison with other melanomas. Livestro DP; Muzikansky A; Kaine EM; Flotte TJ; Sober AJ; Mihm MC; Michaelson JS; Cosimi AB; Tanabe KK J Clin Oncol; 2005 Sep; 23(27):6739-46. PubMed ID: 16170181 [TBL] [Abstract][Full Text] [Related]
13. Early detection of thick melanomas in the United States: beware of the nodular subtype. Demierre MF; Chung C; Miller DR; Geller AC Arch Dermatol; 2005 Jun; 141(6):745-50. PubMed ID: 15967921 [TBL] [Abstract][Full Text] [Related]
14. Phenotypic and Histopathological Tumor Characteristics According to CDKN2A Mutation Status among Affected Members of Melanoma Families. Taylor NJ; Handorf EA; Mitra N; Avril MF; Azizi E; Bergman W; Bianchi-Scarrà G; Bishop DT; Bressac-de Paillerets B; Calista D; Cannon-Albright LA; Cuellar F; Cust AE; Demenais F; Elder DE; Friedman E; Gerdes AM; Ghiorzo P; Goldstein AM; Grazziotin TC; Hansson J; Hayward NK; Hocevar M; Höiom V; Holland EA; Ingvar C; Landi MT; Landman G; Larre-Borges A; Leachman SA; Mann GJ; Nagore E; Olsson H; Palmer J; Perić B; Pjanova D; Puig S; Schmid H; van der Stoep N; Tucker MA; Wadt KAW; Whitaker L; Yang XR; Newton Bishop JA; Gruis NA; Kanetsky PA; J Invest Dermatol; 2016 May; 136(5):1066-1069. PubMed ID: 26827760 [No Abstract] [Full Text] [Related]
15. Screening and surveillance of patients at high risk for malignant melanoma result in detection of earlier disease. Masri GD; Clark WH; Guerry D; Halpern A; Thompson CJ; Elder DE J Am Acad Dermatol; 1990 Jun; 22(6 Pt 1):1042-8. PubMed ID: 2370329 [TBL] [Abstract][Full Text] [Related]
16. Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample. Begg CB; Orlow I; Hummer AJ; Armstrong BK; Kricker A; Marrett LD; Millikan RC; Gruber SB; Anton-Culver H; Zanetti R; Gallagher RP; Dwyer T; Rebbeck TR; Mitra N; Busam K; From L; Berwick M; J Natl Cancer Inst; 2005 Oct; 97(20):1507-15. PubMed ID: 16234564 [TBL] [Abstract][Full Text] [Related]
17. Melanoma staging: Varying precision and terminal digit clustering in Breslow thickness data is evident in a population-based study. Veierød MB; Page CM; Aaserud S; Bassarova A; Jacobsen KD; Helsing P; Robsahm TE J Am Acad Dermatol; 2018 Jul; 79(1):118-125.e1. PubMed ID: 29580861 [TBL] [Abstract][Full Text] [Related]
18. Clinical and histopathological features of malignant melanoma in germline CDKN2A mutation families. Måsbäck A; Olsson H; Westerdahl J; Sandberg T; Borg A; Jonsson N; Ingvar C Melanoma Res; 2002 Dec; 12(6):549-57. PubMed ID: 12459644 [TBL] [Abstract][Full Text] [Related]
19. Distribution of subsequent primary invasive melanomas following a first primary invasive or in situ melanoma Queensland, Australia, 1982-2010. Youlden DR; Youl PH; Soyer HP; Aitken JF; Baade PD JAMA Dermatol; 2014 May; 150(5):526-34. PubMed ID: 25093216 [TBL] [Abstract][Full Text] [Related]
20. CDKN2A germ-line mutations in individuals with multiple cutaneous melanomas. Hashemi J; Platz A; Ueno T; Stierner U; Ringborg U; Hansson J Cancer Res; 2000 Dec; 60(24):6864-7. PubMed ID: 11156381 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]